middle.news
Epsilon Pharma Secures AU$6M Deal to Manufacture Cannabis Products for UK and Europe
11:32am on Thursday 5th of February, 2026 AEDT
•
Healthcare
Read Story
Epsilon Pharma Secures AU$6M Deal to Manufacture Cannabis Products for UK and Europe
11:32am on Thursday 5th of February, 2026 AEDT
Key Points
Three-year manufacturing agreement with Puro New Zealand
Forecast AU$6 million revenue over initial term
Manufacturing and GMP certification of finished cannabis products
Initial UK market launch in Q1 2026 with European expansion planned
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Epsilon Healthcare (ASX:EPN)
OPEN ARTICLE